FEN1 and breast carcinoma: In vivo and in vitro studies have demonstrated that FEN1 is frequently overexpressed in various cancers, such as breast cancer, glioma, and hepatocellular cancer, and that its upregulation promotes tumorigenesis and cancer progression[47–50].